Eli Lilly announced plans to buy obesity drug developer Versanisopens in a new tab or window for $1.93 billion during early-stage trials of its investigational drug bimagrumabopens in a new tab or window -- a first-in-class monoclonal antibody that binds activin type II A and B receptors, which reduces fat mass and increases lean muscle mass in patients with obesity and type 2 diabetes.
|